Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
Status:
Recruiting
Trial end date:
2022-01-22
Target enrollment:
Participant gender:
Summary
This will be an open-label, randomized controlled trial which compares continued treatment
with high dose prednisone (standard therapy) to treatment with rituximab in patients with
minimal change disease or focal segmental glomerulosclerosis unresponsive to 8 weeks of high
dose prednisone .
patients either receive 2 doses of Rituximab 375 mg/m2 iv at time 0 and 14 days with
termination of prednisone or standard therapy which consist of 8 additional weeks of high
dose prednisone treatment.